Show simple item record

dc.contributor.authorBeckmann, Klaus Martin
dc.date.accessioned2018-05-08T04:17:31Z
dc.date.available2018-05-08T04:17:31Z
dc.date.issued2013
dc.date.modified2014-02-07T06:16:28Z
dc.identifier.issn0025-729X
dc.identifier.doi10.5694/mja13.10086
dc.identifier.urihttp://hdl.handle.net/10072/56605
dc.description.abstractConflicting information about treatments is known to undermine compliance with the use of medications.1 The education of patients and caregivers that accompanies prescribing should therefore be as consistent as possible. Clients may conduct research on the internet into particular medicines and try to corroborate “what the doctor said”. In the case of the use of clonidine in children, publicly available information is conflicting. The websites of two regulatory agencies, the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States, give conflicting information on using this α-2 adrenergic agonist. Doctors in Australia may refer patients to the TGA website for information on clonidine, but in doing so will only provide information on the use of clonidine for hypertension. However, paediatricians and child and adolescent psychiatrists may use clonidine (following guidance used in other countries) in children and adolescents for diverse beneficial effects in managing attention deficit-hyperactivity disorder (ADHD), outside its TGA-approved use.2
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAustralasian Medical Publishing Company
dc.publisher.placeAustralia
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom28
dc.relation.ispartofpageto29
dc.relation.ispartofissue1
dc.relation.ispartofjournalMedical Journal of Australia
dc.relation.ispartofvolume199
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchPsychology and Cognitive Sciences
dc.subject.fieldofresearchcode119999
dc.subject.fieldofresearchcode11
dc.subject.fieldofresearchcode17
dc.titleConflicting information from TGA versus FDA may undermine compliance with use of medication
dc.typeJournal article
dc.type.descriptionC3 - Articles (Letter/ Note)
dc.type.codeC - Journal Articles
dc.description.versionPublished
gro.facultyGriffith Health, School of Medicine
gro.rights.copyrightBeckmann KM. Conflicting information from TGA versus FDA may undermine compliance with use of medication. Med J Aust 2013; 199 (1): 28-29. © Copyright 2013 The Medical Journal of Australia – reproduced with permission.
gro.date.issued2013
gro.hasfulltextFull Text
gro.griffith.authorBeckmann, Martin K.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record